Michael Makris/LinkedIn
Nov 12, 2025, 04:42
Michael Makris on FDA Approval of GEVV-HEM Gene Therapy for Hemophilia
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”A biotechnology company (GeneVentiv Therapeutics) has received positive FDA feedback to develop their GEVV-HEM gene therapy for hemophilia.
This is AAV based gene therapy with human factor Va as the insert.
I will want a lot of animal data showing lack of thrombogenicity before human trials.”
Read the announcement here.
Stay updated with Hemostasis Today.
-
Apr 12, 2026, 13:38Emmanuel J Favaloro: D-dimer testing in VTE diagnostic management studies
-
Apr 12, 2026, 13:26Flora Peyvandi: What Can Be Alternative to Warfarin
-
Apr 12, 2026, 13:21Can We Better Predict Who Is Most Likely to Have Another VTE After a First Event? – RPTH Journal
-
Apr 12, 2026, 13:18Gareth Owens: Advancing Aortic Disease Awareness Through Think Aorta
-
Apr 12, 2026, 13:11Denis Oduor: Apheresis Donation and Blood Component Therapy
-
Apr 12, 2026, 13:04Arsene Mekinian Featured in the Journal of Internal Medicine – Santé Arménie
-
Apr 12, 2026, 13:04Toward Nationwide Hemophilia Care in Armenia by 2030 – WFH
-
Apr 12, 2026, 12:56Chokri Ben Lamine: Clinical Dosing and Special Populations Guide for Apixaban
-
Apr 12, 2026, 12:04Riccardo Fumagalli: Long Term Complications Following Catheter Directed Thrombolysis in PE